Quarterly report · Q1
3055.TEDINET S100RKMW
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥68.0bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥262.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥64.0bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥577m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥568m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥818m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥811m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥817m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥497m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥831m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥497m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥831m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥144.4bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥137.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥139.3bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥85.6bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥80.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.7bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥57.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥55.9bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.0bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.0bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.9bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥828m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.7bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥61m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥244m | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥835m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥191m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥22.66 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.41 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.86 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-04-01 → 2023-06-30 | ¥1.1bn |
| Otherother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥16m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1.0bn |
| Otherother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥692m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥2m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥21m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥412m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥124m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥287m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥18m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥15.8bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥15.7bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥143m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥261m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.0bn |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.0bn |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥25m |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥50.2bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥47.9bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥413m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥71.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥68.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥1.4bn |
| Otherother segments | revenue | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥17m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥985m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2m |
| jpcrp040300-q1r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥50m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥367m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥96m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥270m |
| jpcrp040300-q1r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥8m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥15.7bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥15.6bn |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥117m |
| jpcrp040300-q1r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥312m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥972m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥972m |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥68m |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥46.4bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥44.0bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥344m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥68.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥64.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 492
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in accounts receivable other ope cf | Prior1YTDDuration | 889000000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYTDDuration | 362000000 | JPY |
| Increase decrease in deposits received ope cf | Prior1YTDDuration | 269000000 | JPY |
| Increase decrease in deposits received ope cf | CurrentYTDDuration | 195000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 3000000 | JPY |
| Other net ope cf | CurrentYTDDuration | 194000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 3746000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 5429000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 137000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 147000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -0 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -0 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -828000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -652000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 3055000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 4924000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -398000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -1623000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -44000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -28000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -64000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -65000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 566000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 4000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 4000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -1000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -0 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | 61000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -1714000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -0 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -173000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -222000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -16000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -20000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -191000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -244000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 2925000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 2965000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 21091000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 18022000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 24017000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 20988000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 43996000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 15612000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000DispensingIndustryReportableSegmentsMember | 3326000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E03003-000NursingIndustryReportableSegmentsMember | 972000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |